Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pharmacokinetic DifferencesY-3SafteyMild Hepatic InsufficiencyModerate Hepatic InsufficiencyNormal Hepatic Function
Interventions
DRUG

Y-3 for injection(40mg)

"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."

All Listed Sponsors
lead

Neurodawn Pharmaceutical Co., Ltd.

INDUSTRY